

Amendments to the Specification

Please replace paragraph [0016] with the following replacement paragraph.

[0016] As indicated above, the above-mentioned cholinesterase inhibitors can be utilized to augment the anti-depressant therapy in treating vascular depression. For example, they can be utilized to augment: 1) the SSRI anti-depressants, viz., paroxetine hydrochloride (Paxil®), fluoxetine hydrochloride (Prozac®), sertraline hydrochloride (Zoloft®), citalopram hydrobromide (Celexa®), ~~Paxil®, Prozac®, Zoloft®, Celexa®, Lexapro®,~~ etc.; 2) the SNRI anti-depressants, viz., venlafaxine hydrochloride (Effexor®) ~~[[Effexor®]],~~ etc.; 3) the MAO inhibitor anti-depressants, viz., phenelzine sulfate (Nardil®), tranylcypromine sulfate (Parnate®), ~~Nardil®, Parnate®,~~ etc.; 4) the tricyclic anti-depressants, viz., amitriptyline (Elavil®), desipramine hydrochloride (Norpramin®), ~~Elavil®, Norpramin®,~~ etc.; and 5) other anti-depressants which work somewhat differently, viz., bupropion hydrochloride (Wellbutrin®) and mirtazapine (Remeron®), ~~Wellbutrin® and Remeron®.~~

Please replace paragraph [0017] with the following replacement paragraph.

[0017] As with the cholinesterase inhibitors, the appropriate dosage of anti-depressants will, of course, vary depending upon, e.g., the compound employed, the host, the mode of administration and the nature and severity of the condition being treated. However, in general, satisfactory results are obtained when the anti-depressant is administered in the form that is marketed. More particularly, paroxetine hydrochloride (Paxil®) ~~[[Paxil®]]~~ can be administered in tablet form in a total daily dosage of between 10 mg and 50 mg; hydrochloride (Prozac®) ~~[[Prozac®]]~~ can be administered in tablet form in a total daily dosage of 20 mg; sertraline hydrochloride (Zoloft®) ~~[[Zoloft®]]~~ can be administered in tablet form in a total daily dosage of between 25 mg and 200 mg; citalopram hydrobromide (Celexa®) ~~[[Celexa®]]~~ can be administered in tablet form in a total daily dosage of between 10 mg and 40 mg; escitalopram oxalate (Lexapro®) ~~[[Lexapro®]]~~ can be administered in tablet form at a total daily dosage of between 10 mg and 20 mg; venlafaxine hydrochloride (Effexor®) ~~[[Effexor®]]~~ can be administered in tablet form at a daily dosage of between 25 mg and 100 mg; phenelzine sulfate (Nardil®) ~~[[Nardil®]]~~ can be administered in tablet form at a total daily dosage of 15 mg; tranylcypromine sulfate (Parnate®) ~~[[Parnate®]]~~ can be administered in tablet form at a total daily dosage of 10 mg; amitriptyline (Elavil®) ~~Elavil®, which is now marketed as amitriptyline,~~ can be administered in tablet form at a total daily dosage of between 10 mg and 150 mg; desipramine hydrochloride (Norpramin®) ~~[[Norpramin®]]~~ can be administered in tablet form at a total daily dosage of between 10 mg and 150 mg; bupropion hydrochloride (Wellbutrin®)

[[Wellbutrin®]] can be administered in tablet form at a total daily dosage of between 75 mg and 100 mg; and mirtazapine (Remeron®) [[Remeron®]] can be administered in tablet form at a total daily dosage of between 15 mg and 45 mg.

Please replace paragraph [0018] with the following replacement paragraph.

[0018] Moreover, the present invention also pertains to a pharmaceutical composition comprising, in combination, a cholinesterase inhibitor and an anti-depressant, preferably a pharmaceutical composition comprising, in combination, a cholinesterase inhibitor selected from rivastigmine tartrate (Exelon®), donepezil hydrochloride (Aricept®) and galanthamine hydrobromide (Reminyl®) ~~Exelon®, Aricept® and Reminyl®~~ and an anti-depressant selected from SSRI anti-depressants, SNRI anti-depressants, MAO inhibitor anti-depressants, tricyclic anti-depressants, bupropion hydrochloride (Wellbutrin®) and mirtazapine (Remeron®) ~~Wellbutrin® and Remeron®~~, more preferably a pharmaceutical composition comprising, in combination, a cholinesterase inhibitor selected from rivastigmine tartrate (Exelon®), donepezil hydrochloride (Aricept®) and galanthamine hydrobromide (Reminyl®) ~~Exelon®, Aricept® and Reminyl®~~ and an anti-depressant selected from paroxetine hydrochloride (Paxil®), fluoxetine hydrochloride (Prozac®), sertraline hydrochloride (Zoloft®), citalopram hydrobromide (Celexa®), escitalopram oxalate (Lexapro®), venlafaxine hydrochloride (Effexor®), phenelzine sulfate (Nardil®), tranylcypromine sulfate (Parnate®), amitriptyline (Elavil®), desipramine hydrochloride (Norpramin®), bupropion hydrochloride (Wellbutrin®) and mirtazapine (Remeron®) ~~Paxil®, Prozac®, Zoloft®, Celexa®, Lexapro®, Effexor®, Nardil®, Parnate®, amitriptyline, Norpramin®, Wellbutrin® and Remeron®~~, most preferably a pharmaceutical composition comprising, in combination, ~~Exelon®~~ and an anti-depressant selected from paroxetine hydrochloride (Paxil®), fluoxetine hydrochloride (Prozac®), sertraline hydrochloride (Zoloft®), citalopram hydrobromide (Celexa®), escitalopram oxalate (Lexapro®), venlafaxine hydrochloride (Effexor®), phenelzine sulfate (Nardil®), tranylcypromine sulfate (Parnate®), amitriptyline (Elavil®), desipramine hydrochloride (Norpramin®), bupropion hydrochloride (Wellbutrin®) and mirtazapine (Remeron®) ~~Paxil®, Prozac®, Zoloft®, Celexa®, Lexapro®, Effexor®, Nardil®, Parnate®, amitriptyline, Norpramin®, Wellbutrin® and Remeron®~~.

Please replace paragraph [0021] with the following replacement paragraph.

[0021] Accordingly, the present invention also provides a commercial package comprising a combination as disclosed herein together with instructions for simultaneous or sequential use thereof in the treatment of vascular depression, preferably late-onset vascular depression. A preferred commercial package is one wherein one of the active ingredients is rivastigmine tartrate (Exelon®) [[Exelon®]].